{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T04:31:55Z","timestamp":1742358715769,"version":"3.40.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,12,13]],"date-time":"2024-12-13T00:00:00Z","timestamp":1734048000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,13]],"date-time":"2024-12-13T00:00:00Z","timestamp":1734048000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Gen-\u0130la\u00e7"},{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s10072-024-07929-3","type":"journal-article","created":{"date-parts":[[2024,12,13]],"date-time":"2024-12-13T10:38:20Z","timestamp":1734086300000},"page":"1799-1805","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Anti-JCV antibody index seroconversion in Turkish multiple sclerosis patients treated with natalizumab"],"prefix":"10.1007","volume":"46","author":[{"given":"Edanur","family":"\u015eahin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tuncay","family":"G\u00fcnd\u00fcz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed Serkan","family":"Emekli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mazlum","family":"Ercano\u011flu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sevda \u00d6zt\u00fcrk","family":"Erden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3286-2652","authenticated-orcid":false,"given":"Murat","family":"K\u00fcrt\u00fcnc\u00fc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,12,13]]},"reference":[{"key":"7929_CR1","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1001\/jamaneurol.2013.598","volume":"70","author":"R Rudick","year":"2013","unstructured":"Rudick R, Polman C, Clifford D, Miller D, Steinman L (2013) Natalizumab: bench to bedside and beyond. JAMA Neurol 70:172\u2013182","journal-title":"JAMA Neurol"},{"key":"7929_CR2","unstructured":"US Food and Drug Administration Drug Safety Communication: Risk of Progressive Multifocal Leukoencephalopathy (PML) with the use of Tysabri (natalizumab). https:\/\/www.fda.gov\/drugs\/postmarket-drug-safety-information-patients-and-providers\/fda-drug-safety-communication-risk-progressive-multifocal-leukoencephalopathy-pml-use-tysabri Accessed 4 February 2024"},{"key":"7929_CR3","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1111\/apm.12128","volume":"121","author":"HH Hirsch","year":"2013","unstructured":"Hirsch HH, Kardas P, Kranz D, Leboeuf C (2013) The human JC polyomavirus (JCPyV): virological background and clinical implications. APMIS 121:685\u2013727","journal-title":"APMIS"},{"key":"7929_CR4","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1212\/WNL.0000000000008243","volume":"93","author":"LZ Ryerson","year":"2019","unstructured":"Ryerson LZ, Foley J, Chang I et al (2019) Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing. Neurology 93:1452\u20131462","journal-title":"Neurology"},{"key":"7929_CR5","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1177\/1073274817729901","volume":"24","author":"C Bohra","year":"2017","unstructured":"Bohra C, Sokol L, Dalia S (2017) Progressive Multifocal Leukoencephalopathy and Monoclonal Antibodies: A Review. Cancer Control 24:4","journal-title":"Cancer Control"},{"key":"7929_CR6","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1007\/s00415-016-8217-x","volume":"263","author":"RP Maas","year":"2016","unstructured":"Maas RP, Muller-Hansma AH, Esselink RA et al (2016) Drug-associated progressive multifocal leukoencephalopathy: a clinical, radiological, and cerebrospinal fluid analysis of 326 cases. J Neurol 263:2004\u20132021","journal-title":"J Neurol"},{"key":"7929_CR7","first-page":"109","volume":"9","author":"M Kartau","year":"2019","unstructured":"Kartau M, Sipil\u00e4 JO, Auvinen E, Palom\u00e4ki M, Verkkoniemi-Ahola A (2019) Progressive Multifocal Leukoencephalopathy: Current Insights. Degener Neurol Neuromuscul Dis 9:109\u2013121","journal-title":"Degener Neurol Neuromuscul Dis"},{"key":"7929_CR8","unstructured":"Tysabri Safety Considerations, 2023, Biogen data on file. https:\/\/www.tysabri.com\/en_us\/home\/about\/safety-considerations.html. Accessed 4 February 2024"},{"key":"7929_CR9","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1177\/1352458511435105","volume":"18","author":"PS S\u00f8rensen","year":"2012","unstructured":"S\u00f8rensen PS, Bertolotto A, Edan G et al (2012) Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab. Mult Scler 18:143\u2013152","journal-title":"Mult Scler"},{"key":"7929_CR10","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1056\/NEJMoa1107829","volume":"366","author":"G Bloomgren","year":"2012","unstructured":"Bloomgren G, Richman S, Hotermans C et al (2012) Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med 366:1870\u20131880","journal-title":"N Engl J Med"},{"key":"7929_CR11","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1002\/ana.24286","volume":"76","author":"T Plavina","year":"2014","unstructured":"Plavina T, Subramanyam M, Bloomgren G et al (2014) Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol 76:802\u2013812","journal-title":"Ann Neurol"},{"key":"7929_CR12","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1371\/journal.pone.0174005","volume":"12","author":"H Hegen","year":"2017","unstructured":"Hegen H, Auer M, Bsteh G et al (2017) Stability and predictive value of anti-JCV antibody index in multiple sclerosis: A 6-year longitudinal study. PLoS ONE 12:3","journal-title":"PLoS ONE"},{"key":"7929_CR13","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.msard.2019.02.019","volume":"30","author":"J Kolcava","year":"2019","unstructured":"Kolcava J, Hulova M, Benesova Y, Bednarik J, Stourac P (2019) The value of anti-JCV antibody index assessment in multiple sclerosis patients treated with natalizumab with respect to demographic, clinical and radiological findings. Mult Scler Relat Disord 30:187\u2013191","journal-title":"Mult Scler Relat Disord"},{"key":"7929_CR14","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.jocn.2017.08.006","volume":"45","author":"I Correia","year":"2017","unstructured":"Correia I, Jesus-Ribeiro J, Batista S et al (2017) Anti-JCV antibody serostatus and longitudinal evaluation in a Portuguese Multiple Sclerosis population. J Clin Neurosci 45:257\u2013260","journal-title":"J Clin Neurosci"},{"key":"7929_CR15","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1111\/ene.12988","volume":"23","author":"A Vennegoor","year":"2016","unstructured":"Vennegoor A, van Rossum JA, Leurs C et al (2016) High cumulative JC virus seroconversion rate during long-term use of natalizumab. Eur J Neurol 23:1079\u20131085","journal-title":"Eur J Neurol"},{"key":"7929_CR16","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1177\/2040622313514790","volume":"5","author":"JA Nicholas","year":"2014","unstructured":"Nicholas JA, Racke MK, Imitola J, Boster AL (2014) First-line natalizumab in multiple sclerosis: rationale, patient selection, benefits and risks. Ther Adv Chronic Dis 5:62\u201368","journal-title":"Ther Adv Chronic Dis"},{"key":"7929_CR17","doi-asserted-by":"publisher","first-page":"104251","DOI":"10.1016\/j.msard.2022.104251","volume":"68","author":"M Gaughan","year":"2022","unstructured":"Gaughan M, Gilligan M, Patterson I et al (2022) Longitudinal stability of JCV antibody index in Natalizumab treated people with multiple sclerosis. Mult Scler Relat Disord 68:104251","journal-title":"Mult Scler Relat Disord"},{"key":"7929_CR18","doi-asserted-by":"publisher","first-page":"175628642199891","DOI":"10.1177\/1756286421998915","volume":"14","author":"CM Dwyer","year":"2021","unstructured":"Dwyer CM, Jokubaitis VG, Stankovich J et al (2021) High rates of JCV seroconversion in a large international cohort of natalizumab-treated patients. Ther Adv Neurol Disord 14:1756286421998915","journal-title":"Ther Adv Neurol Disord"},{"key":"7929_CR19","doi-asserted-by":"publisher","first-page":"579438","DOI":"10.3389\/fneur.2020.579438","volume":"11","author":"I Toboso","year":"2020","unstructured":"Toboso I, Tejeda-Velarde A, Alvarez-Lafuente R et al (2020) New Algorithms Improving PML Risk Stratification in MS Patients Treated with Natalizumab. Front Neurol 11:579438","journal-title":"Front Neurol"},{"key":"7929_CR20","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.3390\/jcm10091998","volume":"10","author":"R Bonek","year":"2021","unstructured":"Bonek R, Guenter W, Ja\u0142owi\u0144ski R et al (2021) JC Virus Seroprevalence and JCVAb Index in Polish Multiple Sclerosis Patients Treated with Immunomodulating or Immunosuppressive Therapies. J Clin Med 10:1998","journal-title":"J Clin Med"},{"key":"7929_CR21","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1007\/s10096-018-3204-z","volume":"37","author":"M Auer","year":"2018","unstructured":"Auer M, Bsteh G, Hegen H et al (2018) Smoking is not associated with higher prevalence of JC virus in MS patients. Eur J Clin Microbiol Infect Dis 37:907\u2013910","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"2","key":"7929_CR22","doi-asserted-by":"publisher","first-page":"347","DOI":"10.3390\/jcm11020347","volume":"11","author":"C Prezioso","year":"2022","unstructured":"Prezioso C, Ciotti M, Brazzini G et al (2022) Diagnostic Value of JC Polyomavirus Viruria, Viremia, Serostatus and microRNA Expression in Multiple Sclerosis Patients Undergoing Immunosuppressive Treatment. J Clin Med 11(2):347","journal-title":"J Clin Med"},{"issue":"3","key":"7929_CR23","doi-asserted-by":"publisher","first-page":"468","DOI":"10.3390\/v13030468","volume":"13","author":"S Agostini","year":"2021","unstructured":"Agostini S, Mancuso R, Costa AS et al (2021) JCPyV miR-J1-5p in Urine of Natalizumab-Treated Multiple Sclerosis Patients. Viruses 13(3):468","journal-title":"Viruses"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-024-07929-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-024-07929-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-024-07929-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T17:55:35Z","timestamp":1742320535000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-024-07929-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,13]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["7929"],"URL":"https:\/\/doi.org\/10.1007\/s10072-024-07929-3","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"type":"print","value":"1590-1874"},{"type":"electronic","value":"1590-3478"}],"subject":[],"published":{"date-parts":[[2024,12,13]]},"assertion":[{"value":"22 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Clinical Research Ethics Committee of the Istanbul University, Istanbul Faculty of Medicine (E-29624016\u2013050.99\u20131626160).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Due to the retrospective design of the study, signed consent was not obtained from the participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"M.K. has received honoraria, travel support, and research funds from Merck, Novartis, Sanofi, Roche, Teva, Gen \u0130la\u00e7, Abdi \u0130brahim, and ARIS, and has served on advisory boards for these companies. T.G. has received honoraria and travel support from Merck, Novartis, Sanofi, Teva, Gen \u0130la\u00e7, Roche, Abdi \u0130brahim, and ARIS, and has served on advisory boards for these companies. M.E. is employed by Gen \u0130la\u00e7. A.S.E., E.\u015e. and S.\u00d6.E. declare that they have no conflict of interest related to this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}